文献速递妇科

血管生成肿瘤表型预测卵巢癌不良预后

An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2023-02-07

该研究对三个独立队列进行回顾性分析,在195例卵巢癌起始队列中建立0至3分的肿瘤血管生成转录评分,并在TCGA队列(n=582)和ICON7试验的GEO数据集GSE140082(n=380)中验证。结果显示该评分可预测无进展生存期和总生存期,但未与贝伐珠单抗治疗获益相关。

要点

  • 基于7个血管生成相关基因mRNA表达建立的0–3分肿瘤血管生成评分可预测卵巢癌患者的无进展生存期和总生存期(p<0.001)。
  • 肿瘤PDGFA表达是无进展生存期(HR 2.46,p=0.005)和总生存期(HR 2.26,p=0.011)的独立预测因素。
  • 在ICON7试验数据中,血管生成评分与贝伐珠单抗治疗获益无关。

核心结论

  • 卵巢癌中血管生成相关基因的肿瘤表达提示预后不良。
  • 所建立的评分可用于识别对靶向血管生成治疗有应答的患者,该概念需前瞻性对照临床试验验证。

研究设计与样本

  • 回顾性分析三个独立队列:起始卵巢癌队列(n=195)、TCGA公开队列(n=582)和ICON7试验的GEO数据集GSE140082(n=380)。
  • 在起始队列中量化7个血管生成基因(VEGF、VEGFR2、PDGFA、PDGFB、PDGFRA、PDGFRB、KIT)的mRNA表达,建立0至3分的肿瘤血管生成转录评分,并与无进展生存期和总生存期关联。
  • 在TCGA队列中验证该评分,并在GSE140082数据集中分析该评分对贝伐珠单抗治疗疗效的预测作用。

主要发现

  • 起始队列中,肿瘤血管生成评分可预测卵巢癌患者的无进展生存期和总生存期(p<0.001,分别)。
  • 肿瘤PDGFA表达是无进展生存期的独立预测因素(HR 2.46,p=0.005),也是总生存期的独立预测因素(HR 2.26,p=0.011)。
  • 高肿瘤转录血管生成评分是无进展生存期的独立预测因素(HR 1.41,p=0.018)。
  • 在TCGA队列中,转录血管生成评分对无进展生存期有显著但效应量较小的作用。
  • 在ICON7试验中,血管生成评分与贝伐珠单抗治疗获益无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Epithelial ovarian cancer (OC) is the deadliest gynecological malignancy worldwide. Blocking angiogenesis with bevacizumab, an antibody targeting vascular endothelial growth factor (VEGF), shows efficacy in different lines of OC therapy. This study investigates the clinical impact of tumoral expression of angiogenesis-related genes and their association with bevacizumab response in OC in retrospective analysis of three independent cohorts. METHODS: mRNA expression of seven angiogenic genes (VEGF, VEGFR2, PDGFA, PDGFB, PDGFRA, PDGFRB, KIT) was quantified in an inception OC cohort (n = 195) and a transcriptional tumor angiogenesis score from 0 to 3 was established and linked to progression-free survival (PFS) and overall survival (OS). This score was corroborated in an independent publicly available cohort from The Cancer Genome Atlas (TCGA, n = 582) and prediction of therapeutic efficacy of bevacizumab by the angiogenesis score was analyzed in the Gene Expression Omnibus (GEO) dataset GSE140082 (n = 380) from the ICON7-trial. RESULTS: The tumor angiogenesis score prognosticated PFS and OS in patients with OC from the inception cohort (p < 0.001, respectively). Tumoral PDGFA expression (PFS: HR 2.46, p = 0.005; OS: HR 2.26, p = 0.011) and a high tumoral transcriptional angiogenesis score (PFS: HR 1.41, p = 0.018) were identified as independent predictors of clinical outcome. The transcriptional angiogenesis score exhibited a significant though smaller effect size on PFS in the TCGA cohort. However, in the ICON7-trial, the angiogenesis score was not associated with benefit of bevacizumab treatment. CONCLUSIONS: Our study indicates that tumoral expression of angiogenic genes is unfavorable in OC. The established score could be used to identify patients who respond to targeted angiogenic therapies, a concept that warrants prospective controlled clinical trials.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wieser V, Tsibulak I, Reimer DU, et al. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer. Gynecol Oncol. 2023. PMID: 36758419. doi:10.1016/j.ygyno.2023.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。